MabThera (rituximab) 100mg 2 vial ROCHE, The Netherlands

Interchangeable drugs with the same active ingredient:

Mabthera

Reditux

Rituxim

Acellbia

Indications.

MabThera ® is indicated for adults in the following cases:

non-Hodgkin's lymphoma

Monotherapy in patients with stage III-IV follicular lymphoma who are resistant to chemotherapy or are in the stage of a second or subsequent relapse after chemotherapy.

Treatment of CD20-positive diffuse large B-cell non-Hodgkin's lymphoma in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisolone).

Treatment of previously untreated stage III-IV follicular lymphoma in combination with chemotherapy.

Maintenance therapy of follicular lymphomas after receiving a response to induction therapy.

chronic lymphocytic leukemia

Treatment of previously untreated and relapsed/refractory chronic lymphocytic leukemia in combination with chemotherapy. There are only limited data on efficacy and safety in patients previously treated with monoclonal antibodies, including MabThera® , or in patients refractory to previous treatment with MabThera plus chemotherapy.

rheumatoid arthritis

Treatment of severe rheumatoid arthritis (active form) in adults in combination with methotrexate when treatment with other disease-modifying antirheumatic drugs (FMDs) has failed or is intolerable, including treatment with one or more tumor necrosis factor inhibitors.

When used in combination with methotrexate, MabThera ® reduces the rate of progression of destructive changes in the joints according to radiographic data and improves physical function.

Granulomatosis with polyangiitis and microscopic polyangiitis

Treatment of severe forms of active granulomatosis with polyangiitis (Wegener's granulomatosis) and microscopic polyangiitis in combination with corticosteroids to induce remission in adult patients